These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
70 related articles for article (PubMed ID: 4208713)
21. In vitro-in vivo correlation of drug metabolism--deamination of 1- -D-arabinofuranosylcytosine. Dedrick RL; Forrester DD; Ho DH Biochem Pharmacol; 1972 Jan; 21(1):1-16. PubMed ID: 4500983 [No Abstract] [Full Text] [Related]
22. Plasma and cerebrospinal fluid pharmacokinetics of 1-beta-D-arabinofuranosylcytosine and 1-beta-D-arabinofuranosyluracil following the repeated intravenous administration of high- and intermediate-dose 1-beta-D-arabinofuranosylcytosine. Damon LE; Plunkett W; Linker CA Cancer Res; 1991 Aug; 51(16):4141-5. PubMed ID: 1868435 [TBL] [Abstract][Full Text] [Related]
23. Enhancement by tetrahydrouridine of 1-beta-D-arabinofuranosylcytosine (cytarabine) oral activity in L1210 leukemic mice. Neil GL; Moxley TE; Manak RC Cancer Res; 1970 Aug; 30(8):2166-72. PubMed ID: 4990003 [No Abstract] [Full Text] [Related]
24. Simultaneous determination of cytosine arabinoside and its metabolite, uracil arabinoside, in human plasma using hydrophilic interaction liquid chromatography with UV detection. Uchiyama M; Takamatsu Y; Ogata K; Matsumoto T; Jimi S; Tamura K; Hara S Biomed Chromatogr; 2013 Jul; 27(7):818-20. PubMed ID: 23420764 [TBL] [Abstract][Full Text] [Related]
25. Separation of 5'-mono-, di- and triphosphates of 1-beta-D-arabinofuranosylcytosine and of 1-beta-D-arabinofuranosyluracil by thin-layer and high pressure liquid chromatography. Kreis W; Greenspan A; Woodcock T; Gordon C J Chromatogr Sci; 1976 Jul; 14(7):331-3. PubMed ID: 956325 [TBL] [Abstract][Full Text] [Related]
26. Relationship of 1-beta-D-arabinofuranosylcytosine in plasma to 1-beta-D-arabinofuranosylcytosine 5'-triphosphate levels in leukemic cells during treatment with high-dose 1-beta-D-arabinofuranosylcytosine. Liliemark JO; Plunkett W; Dixon DO Cancer Res; 1985 Nov; 45(11 Pt 2):5952-7. PubMed ID: 4053067 [TBL] [Abstract][Full Text] [Related]
27. Effects of 1-beta-D-arabinofuranosylcytosine hydrochloride on regenerating bone marrow. Papac RJ; Calabresi P; Hollingsworth JW; Welch AD Cancer Res; 1965 Oct; 25(9):1459-62. PubMed ID: 5323960 [No Abstract] [Full Text] [Related]
28. Pharmacology and toxicology of a seven-day infusion of 1-beta-D-arabinofuranosylcytosine plus uridine in dogs. Perlow L; Ohnuma T; Andrejczuk A; Shafir M; Strauchen J; Holland JF Cancer Res; 1985 Jun; 45(6):2572-7. PubMed ID: 3986795 [TBL] [Abstract][Full Text] [Related]
29. In vivo studies on high-dose 1-beta-D-arabinofuranosylcytosine (HDara-C) and 1-beta-D-arabinofuranosyluracil (ara-U) with respect to pharmacokinetics, cell kinetics, and cytotoxicity in a rat myelocytic leukemia model (BNML). Colly LP; Willemze R; Honders W; vd Hoorn F; Edelbroek PM Semin Oncol; 1985 Jun; 12(2 Suppl 3):49-54. PubMed ID: 3859932 [TBL] [Abstract][Full Text] [Related]
30. Pharmacological disposition in mice of O 2 :2'-anhydro-1- -D-arabinosylcytosine 3'-phosphate, a potential antileukemic agent. Focke JH; Broussard WJ; Nagyvary J Biochem Pharmacol; 1973 Mar; 22(6):703-13. PubMed ID: 4693492 [No Abstract] [Full Text] [Related]
31. Preparation and antitumor activity of 4'-thio analogs of 2,2'-anhydro-1-beta-D-arabinofuranosylcytosine. Ototani N; Whistler RL J Med Chem; 1974 May; 17(5):535-7. PubMed ID: 4830257 [No Abstract] [Full Text] [Related]
32. Nucleosides. XCI. Some chemical properties of the antileukemic agent 2,2'-anhydro-1-beta-D-arabinofuranosyl-5-fluorocytosine. Fox JJ; Otter BA Ann N Y Acad Sci; 1975 Aug; 255():59-70. PubMed ID: 1059375 [No Abstract] [Full Text] [Related]
34. Continuous infusion of high-dose 1-beta-D-arabinofuranosylcytosine: a phase I and pharmacological study. Spriggs DR; Robbins G; Takvorian T; Kufe DW Cancer Res; 1985 Aug; 45(8):3932-6. PubMed ID: 4016760 [TBL] [Abstract][Full Text] [Related]
35. Correspondence Re: L.E. Damon et al., Plasma and cerebrospinal fluid pharmacokinetics of 1-beta-D-arabinofuranosylcytosine and 1-beta-D-arabinofuranosyluracil following the repeated intravenous administration of high- and intermediate-dose 1-beta-D-arabinofuranosylcytosine. Cancer Res., 51: 4141-4145, 1991. Kreis W; Budman DR Cancer Res; 1992 Jul; 52(13):3818-20. PubMed ID: 1617654 [No Abstract] [Full Text] [Related]
36. Studies on the Vilsmeier-Haack reaction. IV. Convenient synthesis of 2,2'-anhydro-1- -D-arabinofuranosylcytosine (2,2'-cyclocytidine) and its derivatives. Kikugawa K; Ichino M J Org Chem; 1972 Jan; 37(2):284-8. PubMed ID: 5013349 [No Abstract] [Full Text] [Related]
37. Sensitive radioimmunoassay for cytarabine and uracil arabinoside in plasma. Sato T; Morozumi M; Kodama K; Kuninaka A; Yoshino H Cancer Treat Rep; 1984 Nov; 68(11):1357-66. PubMed ID: 6498853 [TBL] [Abstract][Full Text] [Related]
38. Extraction and analytic procedures for cytosine arabinoside and 1-beta-D-arabinofuranosyluracil and their 5'-mono-, di-, and tri-phosphates. Kreis W; Gordon C; Gizoni C; Woodcock T Cancer Treat Rep; 1977 Jul; 61(4):643-6. PubMed ID: 195728 [TBL] [Abstract][Full Text] [Related]
39. Degradation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in human leukemic myeloblasts and lymphoblasts. Jamieson GP; Finch LR; Snook M; Wiley JS Cancer Res; 1987 Jun; 47(12):3130-5. PubMed ID: 3472653 [TBL] [Abstract][Full Text] [Related]
40. Rational design of arabinosyl nucleosides as antitumor and antiviral agents. Müller WE Jpn J Antibiot; 1977 Dec; 30 Suppl():104-20. PubMed ID: 612702 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]